Advancing the introduction of new effective and safe therapies for children and adolescents with cancer.

Through its network of member institutions, ITCC facilitates the exchange of knowledge, resources, and expertise to advance the field of paediatric oncology. By fostering collaboration, researchers and clinicians within the consortium can leverage each other's strengths and capabilities to make significant progress in the fight against childhood cancer.

ITCC plays a pivotal role in driving innovation in paediatric oncology and improving outcomes for children and adolescents with cancer. By promoting collaboration and innovation, ITCC is leading the development of cutting-edge therapies with the potential to revolutionize paediatric cancer treatment.

Established in 2003 as a not-for-profit organization under French law, ITCC attained recognition as a European Category 1 Network for Pediatric Research at the European Medicines Agency (EnprEMA) in January 2011. Comprising an extensive network of European paediatric oncology clinical trial sites and research laboratories, ITCC collaborates closely with clinicians, scientists, regulatory bodies, pharmaceutical companies, and patient advocates to achieve its mission.